national
French health regulator reviews use of Avastin to treat AMD
College Statement The RCOphth notes with interest the move by the French health regulator, French National Agency for Medicines and Health Products Safety (ANSM), in asking Roche to provide information on the safety and efficiency of the off-label use of bevacizumab (Avastin) to treat wet age-related macular degeneration (AMD). Ranibizumab (Lucentis), which is licensed as